Astonea Labs reports Rs 10.44 crore H1 cash outflow despite profit

Astonea Labs Limited reported a Rs 10.44 crore net operating cash outflow for the half year ended September 30, 2026, despite a consolidated profit of Rs 4.74 crore. Receivables and prepayments plus inventories used Rs 19.45 crore, while gross borrowings rose to Rs 57.15 crore from Rs 43.00 crore at March 31, 2026.

Why did Astonea Labs report negative operating cash flow?

Astonea Labs reported negative operating cash flow because working-capital movements exceeded its Rs 12.50 crore operating profit before working-capital adjustments. A Rs 9.48 crore increase in trade and other receivables and prepayments, a Rs 9.97 crore inventory increase, and a Rs 1.17 crore reduction in trade and other payables and provisions resulted in Rs 8.11 crore of negative cash generated from operations. Tax payments of Rs 2.34 crore then took the net operating outflow to Rs 10.44 crore.

The outflow was lower than the Rs 12.69 crore reported for the half year ended September 30, 2025. Operating profit before working-capital movements rose to Rs 12.50 crore from Rs 5.39 crore, but inventory changed from a Rs 3.01 crore cash release in the earlier half year to a Rs 9.97 crore cash use in the latest period.

How did inventory and receivables affect Astonea Labs cash flow?

Inventory, receivables and prepayments were the principal cash uses, absorbing Rs 19.45 crore combined during the six months to September 30, 2026. The company recorded a Rs 9.48 crore cash use from trade and other receivables and prepayments, alongside a Rs 9.97 crore use from inventories, while revenue from operations increased to Rs 95.86 crore from Rs 66.29 crore a year earlier.

Inventories stood at Rs 43.57 crore at September 30, 2026, up Rs 9.97 crore from Rs 33.61 crore at March 31, 2026. Trade receivables rose to Rs 53.32 crore from Rs 48.87 crore over the same six months, an increase of Rs 4.45 crore. The larger receivables-and-prepayments cash-flow figure also captures items beyond trade receivables.

Astonea Labs identifies manufacturing of pharmaceutical and cosmetic products as its single operating segment under Indian Accounting Standard 108. Its half-year expenses included Rs 60.69 crore of material consumed and Rs 6.65 crore of traded-goods purchases, while the Rs 7.52 crore increase in finished and traded-goods inventories reduced reported expense. The filing does not provide inventory ageing, receivables ageing or collection-period data.

What were Astonea Labs borrowings at September 2026?

Astonea Labs had Rs 57.15 crore of gross borrowings at September 30, 2026, consisting of Rs 28.80 crore of non-current borrowings and Rs 28.35 crore of current borrowings. This was Rs 14.14 crore above the Rs 43.00 crore total at March 31, 2026, when non-current borrowings were Rs 20.73 crore and current borrowings were Rs 22.27 crore.

The cash-flow statement reports Rs 8.06 crore under receipts or repayment of long-term borrowings and Rs 6.08 crore under receipts or repayment of short-term borrowings in the half year. It also records Rs 1.94 crore of finance costs and Rs 1.94 crore of interest paid. Since the borrowing lines combine receipts and repayments, the filing does not separately show gross debt raised and gross principal repaid.

Lease liabilities were separate from borrowings, with non-current lease liabilities of Rs 3.13 crore at September 30, 2026 and a Rs 26.56 lakh lease-liability cash outflow during the half year. Trade payables totalled Rs 40.52 crore, comprising Rs 6.41 crore due to micro and small enterprises and Rs 34.12 crore due to other creditors. These trade payables are not part of gross borrowings.

Did Astonea Labs remain profitable while cash was negative?

Astonea Labs remained profitable on a consolidated basis, reporting Rs 4.74 crore of profit for the half year ended September 30, 2026, compared with Rs 1.90 crore a year earlier. Revenue from operations increased by Rs 29.57 crore to Rs 95.86 crore, while total expenses rose to Rs 88.58 crore from Rs 64.89 crore. The reported profit and negative operating cash flow therefore moved in different directions because of working-capital cash use.

The cash-flow statement starts with Rs 7.25 crore of profit before tax, then adjusts for Rs 3.63 crore of depreciation and amortisation, Rs 1.94 crore of finance costs, Rs 23.83 lakh of profit on asset disposal and other items. Total comprehensive income was Rs 4.65 crore after an Rs 8.87 lakh other comprehensive loss. Basic and diluted earnings per share were Rs 4.59, compared with Rs 1.97 in the prior-year half.

The consolidated results include associate Damaira Pharmaceuticals Private Limited, which reported Rs 23.69 crore of revenue and Rs 32.47 lakh of net profit for the half year, based on unaudited financial information provided to Astonea Labs. The associate had Rs 88.56 crore of total assets at September 30, 2026. Astonea Labs voluntarily adopted Indian Accounting Standards, or Ind AS, from the financial year beginning April 1, 2026, and restated comparative figures.

What other disclosed matters could affect Astonea Labs cash needs?

Astonea Labs disclosed that a major fire on April 27, 2026 damaged its factory building, plant and machinery, inventories and other assets. Management recognised an insurance claim receivable based on its assessment, pending the insurer's final assessment and settlement. Because inventories were underinsured, the company separately recognised the uninsured inventory loss as an exceptional item.

The company also reversed Rs 84.49 lakh of input tax credit, or ITC, linked to inventories destroyed in the fire. Management said reconciliation of certain ITC mismatches and unavailed or reversed credits remained in progress, with any tax liability, interest or penalties to be recognised after final reconciliation. Cash and cash equivalents were Rs 47.48 lakh at September 30, 2026, compared with Rs 17.91 lakh at March 31, 2026.

Astonea Labs proposed on October 8, 2026 to subscribe to 51% of Longevity Science Private Limited's share capital. The company classified that proposal as a non-adjusting event after the September 30 reporting date under Ind AS 10, meaning no adjustment was made to the reported half-year results. The filing does not state the proposed subscription amount or timing of completion.

Conclusion

Astonea Labs delivered higher half-year revenue and profit but consumed Rs 10.44 crore of operating cash as inventory, receivables and prepayments absorbed funds. The balance-sheet position showed Rs 43.57 crore of inventories, Rs 53.32 crore of trade receivables and Rs 57.15 crore of gross borrowings at September 30, 2026.

The next reported periods should show whether the Rs 19.45 crore working-capital cash use converts into collections and inventory movement, and whether the pending insurance settlement from the April 2026 fire is finalised. Management also has an unresolved ITC reconciliation and a proposed 51% subscription to Longevity Science Private Limited, announced after the reporting date.